| 1. |
- Titova, Olga E, et al.
(författare)
-
Sleep duration and risk of overall and 22 site-specific cancers : A Mendelian randomization study
- 2021
-
Ingår i: International Journal of Cancer. - : John Wiley & Sons. - 0020-7136 .- 1097-0215. ; 148:4, s. 914-920
-
Tidskriftsartikel (refereegranskat)abstract
- Studies of sleep duration in relation to the risk of site-specific cancers other than breast cancer are scarce. Furthermore, the available results are inconclusive and the causality remains unclear. We aimed to investigate the potential causal associations of sleep duration with overall and site-specific cancers using the Mendelian randomization (MR) design. Single-nucleotide polymorphisms associated with the sleep traits identified from a genome-wide association study were used as instrumental variables to estimate the association with overall cancer and 22 site-specific cancers among 367 586 UK Biobank participants. A replication analysis was performed using data from the FinnGen consortium (up to 121 579 individuals). There was suggestive evidence that genetic liability to short-sleep duration was associated with higher odds of cancers of the stomach (odds ratio [OR], 2.22; 95% confidence interval [CI], 1.15-4.30;P= .018), pancreas (OR, 2.18; 95% CI, 1.32-3.62;P= .002) and colorectum (OR, 1.48; 95% CI, 1.12-1.95;P= .006), but with lower odds of multiple myeloma (OR, 0.47; 95% CI, 0.22-0.99;P= .047). Suggestive evidence of association of genetic liability to long-sleep duration with lower odds of pancreatic cancer (OR, 0.44; 95% CI, 0.25-0.79;P= .005) and kidney cancer (OR, 0.44; 95% CI, 0.21-0.90;P= .025) was observed. However, none of these associations passed the multiple comparison threshold and two-sample MR analysis using FinnGen data did not confirm these findings. In conclusion, this MR study does not provide strong evidence to support causal associations of sleep duration with risk of overall and site-specific cancers. Further MR studies are required.
|
|
| 2. |
- Yuan, Shuai, et al.
(författare)
-
Morning Chronotype and Digestive Tract Cancers : Mendelian Randomization Study
- 2023
-
Ingår i: International Journal of Cancer. - : John Wiley & Sons. - 0020-7136 .- 1097-0215. ; 152:4, s. 697-704
-
Tidskriftsartikel (refereegranskat)abstract
- Morning chronotype has been associated with a reduced risk of prostate and breast cancer. However, few studies have examined whether chronotype is associated with digestive tract cancer risk. We conducted a Mendelian randomization (MR) study to assess the associations of chronotype with major digestive tract cancers. A total of 317 independent genetic variants associated with chronotype at the genome-wide significance level (P<5×10-8) were used as instrumental variables from a genome-wide meta-analysis of 449,734 individuals. Summary-level data on overall and six digestive tract cancers, including oesophageal, stomach, liver, biliary tract, pancreatic, and colorectal cancers, were obtained from the UK Biobank (11,952 cases) and FinnGen (7638 cases) study. Genetic liability to morning chronotype was associated with reduced risk of overall digestive tract cancer and cancers of stomach, biliary tract, and colorectum in UK Biobank. The associations for the overall digestive tract, stomach, and colorectal cancers were directionally replicated in FinnGen. In the meta-analysis of the two sources, genetic liability to morning chronotype was associated with a decreased risk of overall digestive tract cancer (odds ratio [OR] 0.94, 95% confidence interval [CI] 0.90-0.98), stomach cancer (OR 0.84, 95% CI 0.73-0.97), and colorectal cancer (OR 0.92, 95% CI 0.87-0.98), but not with the other studied cancers. The associations were consistent in multivariable MR analysis with adjustment for genetically predicted sleep duration, short sleep, insomnia, and body mass index. The study provided MR evidence of inverse associations of morning chronotype with digestive tract cancer, particularly stomach and colorectal cancers. This article is protected by copyright. All rights reserved.
|
|
